Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Non-viral DNA immunotherapies sound promising—yet Immunon’s disclosures are packed with molecular biology, trial protocols, and shifting cash-runway projections. If you have ever searched "What does Immunon report in their SEC filings?" or scrambled to locate Immunon insider trading Form 4 transactions before the market opens, you know how challenging this data hunt can be.
Stock Titan solves the problem. Our AI parses every document—whether it is the Immunon annual report 10-K simplified or an Immunon quarterly earnings report 10-Q filing—and serves concise explanations you can act on. Stop scrolling through clinical tables: our platform flags R&D spend shifts, highlights trial milestones buried in an Immunon 8-K material events explained, and even sends alerts for Immunon Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that turn dense science into plain English—perfect for understanding Immunon SEC documents with AI
- Instant access to Immunon executive stock transactions Form 4 and ownership changes
- Side-by-side financial trend visualizations for rapid Immunon earnings report filing analysis
- Full proxy coverage, so Immunon proxy statement executive compensation details are never missed
- Real-time feeds direct from EDGAR—updates arrive seconds after filing
Whether you’re modeling cash burn or gauging sentiment shifts after a Phase II readout, our tools keep you ahead. From "Immunon SEC filings explained simply" to granular drill-downs of trial expenditures, Stock Titan delivers the clarity professionals require.
Event summary: On August 5, 2025 Imunon, Inc. (IMNN) furnished a press release reporting financial results for the quarter ended June 30, 2025 as Exhibit 99.1. The company had announced on July 29, 2025 that it would hold a conference call on August 5, 2025 to discuss those results; the call was webcast at http://www.imunon.com.
The 8-K clarifies the furnished information is not "filed" under Section 18 of the Exchange Act and contains forward-looking statements subject to a cautionary note in the press release. Exhibits listed are 99.1 (press release) and 104 (Interactive Data). The report is signed by CFO Kimberly Graper and lists principal offices at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311 with phone (609) 896-9100.
Imunon, Inc. filed a Form 8-K on 28 Jul 2025 reporting that its Board of Directors has approved a 15% stock dividend, equal to 0.15 additional shares for every outstanding share and each common-stock equivalent with dividend rights. The Board set 7 Aug 2025 as the record date and 21 Aug 2025 as the payment date. Exhibit 99.1 contains the related press release; no other material events, financial results, or transactions were disclosed. The information in the exhibit is furnished, not filed, under the Exchange Act.
Imunon, Inc. filed a Form 8-K reporting that it amended its Certificate of Incorporation to implement a 1-for-15 reverse stock split of its common stock. The Certificate of Amendment was filed on 21 Jul 2025 and the split becomes effective 25 Jul 2025 at 12:01 a.m. ET.
At the effective time, every fifteen pre-split shares will be combined into one post-split share, reducing the number of outstanding shares from approximately 31.8 million to 2.1 million. Authorized share counts, par value and voting rights remain unchanged. Post-split shares will continue trading on Nasdaq under ticker IMNN with a new CUSIP 15117N701.
No fractional shares will be issued; stockholders otherwise entitled to fractions will receive one whole post-split share. Equiniti Trust Company is the exchange agent. Book-entry holders need not act; broker-held positions adjust automatically. The share reduction is proportionally reflected in all active S-1, S-3 and S-8 registration statements pursuant to Rule 416(b).
FAQ
What is the current stock price of Imunon (IMNN)?
What is the market cap of Imunon (IMNN)?
